Precigen, Inc. (PGEN) is a Healthcare stock trading at $6.85 (as of 2026-09-11), with a market capitalization of $2.45B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Precigen, Inc. develops gene and cellular therapies and offers disease-modifying therapeutics, including related technology platforms such as UltraVector and AdenoVerse and therapy approaches like UltraCAR-T and RheoSwitch. It also develops genetically engineered swine for regenerative medicine and provides reproductive and embryo transfer technologies.
Understand Precigen, Inc.: how it makes money
Precigen develops gene and cellular therapies (PAPZIMEOS for recurrent respiratory papillomatosis being the lead) and sells therapeutics, engineered-animal products, and embryo-transfer services. Commercial revenue is still thin: product sales were $20M of $100M last quarter, and most pipeline assets remain in Phase 1 or 2.
Each novel therapy must clear a multi-year, capital-intensive clinical path before generating meaningful revenue, and the addressable pool per indication is small enough (27,000 US adults for RRP) that a single approval carries the entire commercial story.
Business quality (Strong): Strong business quality on the operational side, but the equity base is still absorbing accumulated development costs, so the shift from pipeline to sustained profit is the defining question.
Bull case
Pivotal trial shows durable remissions: PAPZIMEOS achieved a 51% complete response rate in the PRGN-2012 pivotal study, and 83% of those responders maintained complete response without any additional treatment interventions. For adult RRP, a disease with limited effective therapies, this durability profile supports a compelling value story to payers.
Payer coverage largely in place: Ninety percent of insured lives in the US already have payer coverage for PAPZIMEOS, with an estimated 297 million accessible US lives. This removes the multi-month reimbursement lag that typically stalls a new orphan therapy's revenue ramp.
Operating leverage at current scale: The company posted a 41% operating margin on $100M of quarterly revenue, indicating that fixed manufacturing and R&D costs are being spread over a growing revenue base. As commercial volume for PAPZIMEOS scales, the margin profile has room to expand further.
Bear case
Revenue base is not yet recurring: Net product revenue was only $20M of the $100M quarterly total, and the 6323% YoY revenue surge implies a prior-year base near zero. The remaining $80M likely reflects non-product or one-time items, meaning sustainable product sales are still early and small.
Single-asset, small-pool dependency: The estimated US adult RRP patient population is approximately 27,000, with 125,000 outside the US. Even at full penetration, the single-asset market ceiling is modest relative to the capital-intensive cost of cell-therapy manufacturing and multi-year clinical programs still in Phase 1 or 2.
Equity holders still deeply underwater: Return on equity stands at -158%, meaning accumulated R&D and development losses continue to erode book value. The 41% operating margin has not yet translated into positive shareholder returns, and the path to sustained profitability remains unproven at scale.